Lack of insurance linked to racial, ethnic disparities in cancer diagnoses

Insurance status may explain a disparity in breast cancer diagnoses, with minority women more likely than white women to be diagnosed with late-stage cancer.
Source: Yale Science and Health News - Category: Universities & Medical Training Source Type: news

Related Links:

Publication date: 20 December 2019Source: Journal of Genetics and Genomics, Volume 46, Issue 12Author(s): Yang Duan, Xingyan Zhang, Lihong Yang, Xu Dong, Zhanye Zheng, Yiming Cheng, Hao Chen, Bei Lan, Dengwen Li, Jun Zhou, Chenghao Xuan
Source: Journal of Genetics and Genomics - Category: Genetics & Stem Cells Source Type: research
AbstractOverexpression of either miR ‐302 or miR‐302/367 cluster induces reprogramming of cancer cells and exerts tumor‐suppressive effects by induction of mesenchymal‐to‐epithelial transition, apoptosis and a less proliferative capacity. Several reports have described miR‐16 as a tumor suppressor microRNA (miRNA). Here, we studied the impact of exogenous induction of miR‐16 in MDA‐MB‐231 and SK‐BR‐3 breast cancer cells following overexpression of miR‐302/367 cluster and investigated whether transfection of these cells by a mature miR‐16 mimic could affect the reprogramming state of the cells and ...
Source: IUBMB Life - Category: Research Authors: Tags: RESEARCH COMMUNICATION Source Type: research
Conclusions: Our findings demonstrate that Regorafenib enhanced radiosensitivity of breast cancer cells by inhibiting the expression of multiple receptor tyrosine kinases, VEGF-mediated angiogenesis and DNA damage response in TNBC. Therefore, combining Regorafenib with radiation and antiangiogenic agents will be beneficial and effective in controlling TNBC. PMID: 32052681 [PubMed - as supplied by publisher]
Source: International Journal of Radiation Biology - Category: Radiology Tags: Int J Radiat Biol Source Type: research
ConclusionPharmacokinetic quantitative parameters with histogram and texture features obtained from DCE-MRI are associated with the molecular subtypes of breast cancer, and may serve as potential imaging biomarkers to differentiate between the luminal A and luminal B molecular subtypes.
Source: Academic Radiology - Category: Radiology Source Type: research
Publication date: Available online 15 February 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Ava Kwong, Vivian Yvonne Shin, Jiawei Chen, Isabella Wai-Yin Cheuk, Cecilia YS. Ho, Chun Hang Au, Karen K.L. Chan, Hextan Y.S. Ngan, Tsun Leung Chan, James M. Ford, Edmond SK. MaABSTRACTDifferences in the mutation spectrum across ethnicities suggest that it is important to identify genes in addition to common high penetrant genes to estimate the associated breast cancer risk in Chinese. 1,338 high-risk breast cancer patients who tested negative for germline BRCA1, BRCA2, TP53 and PTEN mutations between 2007-2017 were s...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
Publication date: Available online 14 February 2020Source: Pharmacological ResearchAuthor(s): Qing-Yun Chong, Ze-Hui Kok, Ngoc-Linh-Chi Bui, Xiaoqiang Xiang, Andrea Li-Ann Wong, Wei Peng Yong, Gautam Sethi, Peter E. Lobie, Lingzhi Wang, Boon-Cher GohAbstractCell cycle dysregulation, characterised by aberrant activation of cyclin dependent kinases (CDKs), is a hallmark of cancer. After years of research on the first and second generations of less selective CDK inhibitors with unfavourable clinical activity and toxicity profiles, CDK4/6 inhibitors become the first and only class of highly specific CDK inhibitors being approv...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 antibody drug, is the first-line therapy for human epidermal growth factor receptor 2-positive breast and gastric cancer. For breast cancer, the benefit of continuous treatment with trastuzumab after it becomes refractory to first-line therapy has been demonstrated. However, it is unclear whether trastuzumab can show similar efficacy as a second-line treatment for gastric cancer. Here, we report that trastuzumab in combination with paclitaxel exhibits increased antitumor efficacy even for trastuzumab-resistant xenografted tumors. We derived the trastuzu...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
This study aim at investigating the function of microRNA (miR)-34b-5p in breast cancer prognosis and development. qRT-PCR was used for miR-34b-5p expression examination in breast cancer samples. CCK8, immunohistochemistry, scratch wound healing, transwell assays were performed for cell experiments. Subcutaneously implanted tumor model was carried out for animal experiment. Western blot was conducted for protein expression detection. Bioinformatics analysis was performed for exploring the underlying mechanism. MiR-34b-5p expression was down-regulated in breast cancer samples and cells, and miR-34d-5p could inhibit cell viab...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Conclusion: Collectively, the activation of GPER inhibits cells proliferation, invasion and EMT of triple-negative breast cancer via CD151/miR-199a-3p bio-axis. This study provides a novel intervention target for the treatment of breast cancer cells and a fresh idea for the clinical therapy of breast cancer. PMID: 32051735 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Authors: Garufi G, Palazzo A, Paris I, Orlandi A, Cassano A, Tortora G, Scambia G, Bria E, Carbognin L Abstract Introduction: Despite recent advances in the molecular characterization of triple-negative breast cancer (TNBC), the standard treatment for early-stage TNBC is represented by the historically used anthracycline and taxane-based chemotherapy. In this modern era of precision medicine, several new therapeutic strategies and novel agents have been investigated in the neoadjuvant setting of TNBC, in order to individualize treatment.Areas covered: This review provides a comprehensive overview of the currently a...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Insurance | Science | Universities & Medical Training | Women | Yale